Thrombolytic Science began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of TS01 with or without a C1 esterase inhibitor in 50-70 healthy male volunteers. Thrombolytic Science International LLC , Cambridge, Mass.   Product:...

Toronto-based NoNO Inc. has become the first company to show that macaque models have the potential to derisk clinical testing of new stroke therapies, which typically have gone right from rat or rabbit models into...

Thrombolytic Science International LLC is developing a combination product to target only the clots that lead to stroke, which it expects will significantly reduce bleeding and potentially double the treatment window compared with the only...

Thrombolytic Science International LLC (Cambridge, Mass.) said it has raised $5 million in a series A round from an undisclosed angel investor. In 2010, the company raised $2.5 million in seed funding from the same...